Edition:
India

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

12.07USD
7 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$12.07
Open
$12.20
Day's High
$12.35
Day's Low
$12.04
Volume
84,142
Avg. Vol
111,061
52-wk High
$20.90
52-wk Low
$9.87

Latest Key Developments (Source: Significant Developments)

Athenex Files For Potential Mixed Shelf Offering, Size Not Disclosed
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Athenex Inc ::ATHENEX INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Athenex And Hanmi Pharmaceutical announce strategic realignment of joint projects
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Athenex Inc ::ATHENEX AND ITS COLLABORATIVE PARTNER, HANMI PHARMACEUTICAL, ANNOUNCE STRATEGIC REALIGNMENT OF THEIR JOINT PROJECTS.ATHENEX INC - UNNDER REALIGNMENT, CO TO GET FROM HANMI PHARMACEUTICAL RIGHTS TO KX-01 ORAL FORMULATION FOR KOREA, CHINA & OTHER ASIAN TERRITORIES.ATHENEX - UNDER REALIGNMENT, CO, HANMI PHARMACEUTICAL AGREE TO EXTENSION OF CO'S TERRITORIES TO WORLDWIDE APART FROM KOREA, UNDER ORASCOVERY PROGRAM.  Full Article

Athenex Says Two Phase 3 Pivotal Efficacy Studies Of KX2-391 In Actinic Keratosis Met Primary Endpoints
Thursday, 26 Jul 2018 

July 26 (Reuters) - Athenex Inc ::ATHENEX ANNOUNCES THAT TWO PHASE 3 PIVOTAL EFFICACY STUDIES OF KX2-391 IN ACTINIC KERATOSIS ACHIEVED THEIR PRIMARY ENDPOINTS.ATHENEX INC - STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR BOTH FACE AND SCALP SUBGROUPS AS WELL IN PHASE 3 PIVOTAL EFFICACY STUDIES OF KX2-391.ATHENEX - SECOND INTERIM ANALYSIS RESULTS FROM ONGOING PHASE 3 STUDY ON ORAXOL WILL BE PRESENTED TO DATA AND SAFETY MONITORING BOARD IN LATE Q3 2018.  Full Article

Athenex Receives U.S. FDA Orphan Drug Designation For Oraxol For The Treatment Of Angiosarcoma
Thursday, 19 Apr 2018 

April 19 (Reuters) - Athenex Inc ::ATHENEX, INC. RECEIVES U.S. FDA ORPHAN DRUG DESIGNATION FOR ORAXOL FOR THE TREATMENT OF ANGIOSARCOMA.ATHENEX INC - WILL BE INITIATING ANGIOSARCOMA CLINICAL STUDY SOON.  Full Article

Athenex Inc Q4 Revenue $14.9 Million
Monday, 26 Mar 2018 

March 26 (Reuters) - Athenex Inc ::ATHENEX, INC. ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS.Q4 REVENUE ROSE 191 PERCENT TO $14.9 MILLION.Q4 REVENUE VIEW $20.6 MILLION -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $100 MILLION TO $125 MILLION.QTRLY ‍NET LOSS OF $28.4 MILLION VERSUS NET LOSS OF $40.1 MILLION.‍EXPECT TOPLINE DATA FOR PHASE III KX2-391 OINTMENT STUDIES TO BE AVAILABLE IN Q3 OF 2018​.  Full Article

Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Athenex Inc ::ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL.ATHENEX INC - SECOND INTERIM ANALYSIS OF ORAXOL PHASE III CLINICAL STUDY BASED ON 180 EVALUABLE PATIENTS IS PLANNED FOR MIDDLE OF 2018.  Full Article

Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Athenex Inc ::ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS.ATHENEX INC - ACCEPTANCE OF ORAXOL IND BY CHINESE FDA ALLOWS ATHENEX TO COMMENCE A CLINICAL TRIAL PROGRAM FOR ORAXOL IN CHINA IN 2018.  Full Article

Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Almirall SA ::ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS.ALMIRALL SA - CO AND ATHENEX HAVE ENTERED INTO A PARTNERSHIP TO DEVELOP AND COMMERCIALIZE KX2-391 IN UNITED STATES AND EUROPE.ALMIRALL - ATHENEX WILL GRANT EXCLUSIVE LICENSE TO ALMIRALL TO RESEARCH, COMMERCIALIZE KX2-391 IN THE U.S., EUROPEAN COUNTRIES, INCLUDING RUSSIA.ALMIRALL SA - UNDER TERMS OF PARTNERSHIP AGREEMENT, ATHENEX WILL RECEIVE AN UP-FRONT FEE AND NEAR-TERM PAYMENTS OF UP TO $55 MILLION.ALMIRALL SA - ATHENEX WILL BE ELIGIBLE TO RECEIVE LAUNCH AND ADDITIONAL INDICATIONS MILESTONES FOR $65 MILLION.ALMIRALL SA - DEAL INCLUDES SALES PERFORMANCE MILESTONES OF KX2-391 ESTIMATED TO BE $155 MILLION.ALMIRALL - THERE WILL BE TIERED ROYALTIES STARTING AT 15% BASED ON ANNUAL NET SALES, WITH INCREMENTAL INCREASES IN ROYALTY RATES WITH INCREASED SALES.ALMIRALL SA - ATHENEX WILL BE RESPONSIBLE FOR CONDUCTING ALL PRECLINICAL AND CLINICAL STUDIES UP TO U.S. FDA APPROVAL.  Full Article

Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle
Friday, 1 Dec 2017 

Athenex Inc ::ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE.ATHENEX INC - ‍COMPANY WILL COMMENCE AN EXECUTIVE SEARCH TO IDENTIFY A SUITABLE REPLACEMENT FOR CFO ROLE​.ATHENEX INC - ‍RIEHLE WILL CONTINUE TO SERVE AS AN ADVISOR TO COMPANY​.  Full Article

Athenex announces Q3 revenue of $14 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Athenex Inc :Athenex, Inc. Announces third quarter 2017 results.Q3 revenue rose 149 percent to $14 million.Sees FY 2017 revenue $33 million to $35 million.Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​.FY2017 revenue view $32.3 million -- Thomson Reuters I/B/E/S.Athenex Inc - Sees launch of 4 additional products in Athenex Pharmaceutical division & 2 products in Athenex Pharma solutions in 4Q'17​.  Full Article